Hematology/Oncology

Friedman CF, D'Souza A, Bello Roufai D, Tinker AV, de Miguel M, Gambardella V, Goldman J, Loi S, Melisko ME, Oaknin A, Spanggaard I, Shapiro[...]

By sjmartinez • January 12, 2024

Seitz KP, Baclig NV, Stiller R, Chen A. Implementation of a Near-Peer Support Program to Improve Trainee Well-Being after Patient Safety Events. ATS Sch. 2023[...]

By sjmartinez • January 10, 2024

Pant S, Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Basturk O, VanWyk H, Tavares AM, Seenappa LM, Perry[...]

By sjmartinez • January 10, 2024

Glaspy J, Bondarenko I, Krasnozhon D, Rutty D, Chen J, Fu Y, Wang S, Hou Q, Li S. Efbemalenograstim alfa not inferior to pegfilgrastim in[...]

By sjmartinez • January 10, 2024

Brauer ER, Ganz PA. History and current status of the survivorship care program at the University of California, Los Angeles Jonsson Comprehensive Cancer Center (UCLA[...]

By sjmartinez • January 7, 2024

Oluwole OO, Forcade E, Muñoz J, de Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney P, Goy AH, Kersten MJ, Jacobson CA,[...]

By sjmartinez • January 5, 2024

Winston DJ, Young PA, Schlamm HT, Schiller GJ. Good Outcomes in Therapy of Fusariosis Depend on Both an Effective Drug and the Host. Clin Infect[...]

By sjmartinez • January 5, 2024

Baclig NV, McCann KE. Updates in the treatment of HR+HER2- breast cancer. Curr Opin Obstet Gynecol. 2024 Feb 1;36(1):57-63. doi: 10.1097/GCO.0000000000000925. Epub 2023 Dec 7.[...]

By sjmartinez • January 4, 2024

Britten K, McAndrew N. New approaches for human epidermal growth factor receptor 2-low and human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. Curr Opin[...]

By sjmartinez • January 4, 2024

Shehata MS, Lofftus SY, Park JY, Singh AS, Federman NC, Eilber FC, Crompton JG, McCaw TR. Sarcoma in patients with Lynch syndrome and response to[...]

By sjmartinez • December 28, 2023